We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
oscar aballay
Jul 14, 2021
4
Swapan Kumar Nath
Jul 14, 2021
I suggest trastuzumab deruxtecan
EMADMOHSEN EL-NASHAR
Jul 16, 2021
4
Zuhair ALZIBAIR
Jul 16, 2021
There was a partial response to docetaxel PH initially ...since the goal of the treatment is palliative in principle ,I suggest re-challenge with weekly paclitaxel- trastuzumab pertuzumab
Gail Morris
Jul 16, 2021
5 Start with SBRT to liver, then 4, if the patient agrees. I’m speaking as a physician with ER-PR-HER2+ ductal carcinoma with no recurrence of liver mets after 14 years. The word “palliative” is not in my vocabulary. I never comment on forums but feel like I need to weigh in on this one. If even one oncologist reading this considers SBRT in a case such as this, I will be happy.
Kavi Capildeo
Jul 17, 2021
3 or 4
Barb Stein
Jul 17, 2021
As a RN with Er Pr neg HER2+ with mets to my liver. SBRT to liver mets after 6 rounds of THP followed by H&P (Cleopatra trial). Did the trick for me! 6 years NED on H&P.
Barb Stein
Jul 18, 2021
As she had a reoccurrence 3 years out, first line metastatic would be 1 and since oligometastisis SBRT to any residual met.
surapong supaporn
Jul 18, 2021
Ans. 1
: as cleopatra trial
: recurrent after 3 years completion of adjuvant therapy
:
Rham Zaki
Oct 10, 2021
Rechallange ,,answer no.1
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Ana
C.
Sandoval Leon
MD
oscar aballay
Jul 14, 2021
Swapan Kumar Nath
Jul 14, 2021
EMADMOHSEN EL-NASHAR
Jul 16, 2021
Zuhair ALZIBAIR
Jul 16, 2021
Gail Morris
Jul 16, 2021
Kavi Capildeo
Jul 17, 2021
Barb Stein
Jul 17, 2021
Barb Stein
Jul 18, 2021
surapong supaporn
Jul 18, 2021
Rham Zaki
Oct 10, 2021
Apr 19, 2024
Pending Moderator approval.